Talphera, Inc. (TLPH) SEC filings

TLPHNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30

$0.91−0.13 (-12.46%)

Close on Nov 13, 2026Market cap $47.03MP/E –Yield –

SEC filings

40 of Talphera's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Nov 12, 2026	Nov 12, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 12, 2026	SEC EDGAR
Current report	8-K	Aug 12, 2026	Aug 12, 2026	SEC EDGAR
Current report	8-K	Jun 22, 2026	Jun 23, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 13, 2026	SEC EDGAR
Current report	8-K	May 13, 2026	May 13, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 22, 2026	Apr 29, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 23, 2026	SEC EDGAR
Current report	8-K	Mar 23, 2026	Mar 23, 2026	SEC EDGAR
Current report	8-K	Mar 13, 2026	Mar 16, 2026	SEC EDGAR
Current report	8-K	Mar 11, 2026	Mar 13, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Oct 23, 2025	Oct 24, 2025	SEC EDGAR
Current report	8-K	Oct 20, 2025	Oct 22, 2025	SEC EDGAR
Current report	8-K	Oct 14, 2025	Oct 16, 2025	SEC EDGAR
Current report	8-K	Sep 7, 2025	Sep 10, 2025	SEC EDGAR
Proxy statement	DEF 14A	Oct 23, 2025	Sep 9, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 14, 2025	SEC EDGAR
Current report	8-K	Aug 14, 2025	Aug 14, 2025	SEC EDGAR
Current report	8-K	May 30, 2025	Jun 5, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 14, 2025	SEC EDGAR
Current report	8-K	May 14, 2025	May 14, 2025	SEC EDGAR
Annual report, amended	10-K/A	Dec 31, 2024	Apr 29, 2025	SEC EDGAR
Current report	8-K	Mar 31, 2025	Apr 2, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 31, 2025	SEC EDGAR
Current report	8-K	Mar 31, 2025	Mar 31, 2025	SEC EDGAR
Current report	8-K	Dec 6, 2024	Dec 11, 2024	SEC EDGAR
Current report	8-K	Nov 27, 2024	Nov 29, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 13, 2024	SEC EDGAR
Current report	8-K	Nov 13, 2024	Nov 13, 2024	SEC EDGAR
Current report	8-K	Sep 30, 2024	Oct 1, 2024	SEC EDGAR
Current report	8-K	Aug 12, 2024	Aug 14, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 14, 2024	SEC EDGAR
Current report	8-K	Jun 24, 2024	Jun 24, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 14, 2024	SEC EDGAR
Current report	8-K	May 14, 2024	May 14, 2024	SEC EDGAR
Proxy statement	DEF 14A	Jun 24, 2024	Apr 29, 2024	SEC EDGAR
Current report	8-K	Apr 19, 2024	Apr 19, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Talphera's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Oct 26, 2022
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TLPH.

Compare: TLPH vs TCRT · TLPH vs CRVO · TLPH vs BCDA · TLPH vs KPRX · TLPH vs AZTR

Revenue growth-100.0% · median -74.9%

Company	Revenue	Growth
CRVO	$8.73K	-99.9%
TCRT	$3.00K	-50.0%
TLPH	$0	-100.0%
BCDA	–	–
KPRX	–	–
AZTR	–	–

Company

Next earnings (est.): Mar 22, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 12
Held by institutions: 54.4%
Auditor: BPM LLP
SEC CIK: 1427925

Advertisement
300 × 250

See a number that looks wrong?